2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitors
2001
Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions
Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann M, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood 2001, 97: 818-821. PMID: 11157505, DOI: 10.1182/blood.v97.3.818.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseReed-Sternberg cellsHRS cellsT-cell receptor beta rearrangementsCases of HDClassical Hodgkin's diseaseCoexpression of markersCell fusionNumerical chromosomal abnormalitiesUnusual immunophenotypeT cellsRare caseB cellsBeta rearrangementChromosomal abnormalitiesGermline configurationIgH allelesDifferent hematopoietic lineagesDiseaseHodgkinCell generationCellsTCRbeta allelesHematopoietic lineagesImmunoglobulin genes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply